$599

Regeneron Targets PNPLA3 for MASH; Aurigene and Alveus Extend Collaboration

Two cardiometabolic-related news items have been observed: Regeneron initiated a new Ph2 MASH study (view CT.gov record), and Aurigene is expanding its partnership with Alveus Therapeutics (view LinkedIn post). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here